Insulet Corporation

NasdaqGS:PODD Stock Report

Market Cap: US$18.0b

Insulet Valuation

Is PODD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PODD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PODD ($266.57) is trading above our estimate of fair value ($242.74)

Significantly Below Fair Value: PODD is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PODD?

Key metric: As PODD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for PODD. This is calculated by dividing PODD's market cap by their current earnings.
What is PODD's PE Ratio?
PE Ratio44.4x
EarningsUS$420.90m
Market CapUS$18.00b

Price to Earnings Ratio vs Peers

How does PODD's PE Ratio compare to its peers?

The above table shows the PE ratio for PODD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average56.2x
STE STERIS
34.6x11.5%US$20.2b
DXCM DexCom
45.9x16.6%US$29.6b
ZBH Zimmer Biomet Holdings
19.7x8.1%US$21.1b
BAX Baxter International
124.5x40.5%US$14.8b
PODD Insulet
44.4x2.0%US$18.0b

Price-To-Earnings vs Peers: PODD is good value based on its Price-To-Earnings Ratio (44.4x) compared to the peer average (56.2x).

Price to Earnings Ratio vs Industry

How does PODD's PE Ratio compare vs other companies in the US Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MHUA Meihua International Medical Technologies
0.9xn/aUS$8.04m
PAVM PAVmed
0.4x-90.0%US$6.65m
RTSL Rapid Therapeutic Science Laboratories
0.3xn/aUS$18.99k
No more companies available in this PE range
PODD 44.4xIndustry Avg. 35.2xNo. of Companies9PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: PODD is expensive based on its Price-To-Earnings Ratio (44.4x) compared to the US Medical Equipment industry average (34.5x).

Price to Earnings Ratio vs Fair Ratio

What is PODD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PODD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio44.4x
Fair PE Ratio27.4x

Price-To-Earnings vs Fair Ratio: PODD is expensive based on its Price-To-Earnings Ratio (44.4x) compared to the estimated Fair Price-To-Earnings Ratio (27.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PODD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$266.57
US$285.63
+7.1%
10.5%US$340.00US$234.00n/a22
Dec ’25US$266.78
US$275.31
+3.2%
8.0%US$317.00US$234.00n/a22
Nov ’25US$235.61
US$247.99
+5.3%
9.3%US$285.00US$185.00n/a21
Oct ’25US$234.56
US$242.23
+3.3%
9.2%US$285.00US$185.00n/a21
Sep ’25US$202.77
US$236.85
+16.8%
7.4%US$264.00US$185.00n/a21
Aug ’25US$197.25
US$233.64
+18.4%
9.0%US$270.00US$185.00n/a21
Jul ’25US$196.16
US$233.64
+19.1%
9.0%US$270.00US$185.00n/a21
Jun ’25US$177.19
US$233.64
+31.9%
9.0%US$270.00US$185.00n/a21
May ’25US$170.27
US$236.27
+38.8%
7.0%US$270.00US$208.00n/a20
Apr ’25US$168.10
US$236.13
+40.5%
7.0%US$270.00US$208.00n/a20
Mar ’25US$169.25
US$236.77
+39.9%
7.6%US$270.00US$208.00n/a20
Feb ’25US$195.40
US$232.27
+18.9%
11.5%US$270.00US$163.00n/a20
Jan ’25US$216.98
US$226.72
+4.5%
13.5%US$270.00US$163.00n/a20
Dec ’24US$192.19
US$219.90
+14.4%
16.1%US$280.00US$163.00US$266.7820
Nov ’24US$137.72
US$251.60
+82.7%
21.1%US$355.00US$162.00US$235.6120
Oct ’24US$159.49
US$273.11
+71.2%
17.5%US$355.00US$185.00US$234.5618
Sep ’24US$192.18
US$287.72
+49.7%
15.0%US$355.00US$208.00US$202.7718
Aug ’24US$270.94
US$345.33
+27.5%
8.7%US$375.00US$234.00US$197.2518
Jul ’24US$288.34
US$345.94
+20.0%
8.6%US$375.00US$234.00US$196.1618
Jun ’24US$272.48
US$345.94
+27.0%
8.6%US$375.00US$234.00US$177.1918
May ’24US$318.87
US$337.18
+5.7%
8.7%US$375.00US$234.00US$170.2717
Apr ’24US$318.96
US$331.00
+3.8%
9.3%US$375.00US$234.00US$168.1016
Mar ’24US$282.48
US$328.75
+16.4%
9.8%US$375.00US$234.00US$169.2516
Feb ’24US$290.53
US$311.63
+7.3%
11.7%US$350.00US$216.00US$195.4016
Jan ’24US$294.39
US$309.94
+5.3%
12.0%US$350.00US$216.00US$216.9816
Dec ’23US$308.00
US$302.13
-1.9%
12.0%US$350.00US$216.00US$192.1916

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 06:47
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Insulet Corporation is covered by 58 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anand VankawalaAvondale Partners
Jeffrey JohnsonBaird
null nullBaird